Kristi Rosa

Ahead of the 2026 ASCO Annual Meeting, 3.5-year follow-up findings from the phase 3 EV-302/KEYNOTE-A39 study have been announced.

Data from the ENGOT-ENG-NSGO/GOG-3031/RUBY trial have been released via abstract ahead of the 2026 ASCO Annual Meeting.

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

CHMP recommends camizestrant plus CDK4/6 inhibitor for ESR1-mutated HR+/HER2– advanced breast cancer, based on SERENA-6 phase 3 trial data.

CHMP recommended trastuzumab deruxtecan for HER2-positive (IHC 3+) metastatic solid tumors, marking the first tumor-agnostic ADC opinion in the EU.

Prospective genomic testing defined HRR deficiency across 11 genes, enabling analyses in unselected, HRR-deficient, HRR-nondeficient/unknown, and BRCA-mutated populations. BICR rPFS per PCWG3/RECIST 1.1 showed strong-to-moderate correlations with OS across three models, including frailty variance to address censoring and time-to-event dynamics.

Adjuvant selpercatinib cut recurrence or death risk by 83% vs placebo in stage IB-IIIA RET fusion–positive NSCLC in LIBRETTO-432.

Perioperative apalutamide plus ADT improved metastasis-free survival and pathologic responses in high-risk localized prostate cancer.

Seven-year data from the CROWN study show improved PFS with lorlatinib over crizotinib among patients with ALK-positive non–small cell lung cancer.

FLAME data show ctDNA-guided addition of chemotherapy to osimertinib improved PFS vs osimertinib alone in EGFR-mutant NSCLC.